Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Citi
US Army
Fuji
Covington
Federal Trade Commission
Deloitte

Generated: September 23, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,526,764

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,526,764 protect, and when does it expire?

Patent 9,526,764 protects SOLIQUA 100/33 and is included in one NDA.

This patent has sixty patent family members in thirty-eight countries.

Summary for Patent: 9,526,764
Title:Combination of an insulin and a GLP-1-agonist
Abstract: The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist.
Inventor(s): Werner; Ulrich (Frankfurt am Main, DE), Rotthauser; Barbel (Frankfurt am Main, DE)
Assignee: SANOFI-AVENTIS DEUTSCHLAND GMBH (Frankfurt am Main, DE)
Application Number:13/123,835
Patent Claim Types:
see list of patent claims
Formulation; Compound; Dosage form;

Drugs Protected by US Patent 9,526,764

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Sanofi-aventis Us SOLIQUA 100/33 insulin glargine; lixisenatide SOLUTION;SUBCUTANEOUS 208673-001 Nov 21, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 9,526,764

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany10 2008 051 834Oct 17, 2008
Germany10 2008 053 048Oct 24, 2008
Germany10 2009 038 210Aug 20, 2009
PCT Information
PCT FiledOctober 09, 2009PCT Application Number:PCT/EP2009/063195
PCT Publication Date:April 22, 2010PCT Publication Number: WO2010/043566

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Argus Health
Merck
Baxter
Express Scripts
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.